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Abstract
Studies on the effectiveness of ultrafiltration (UF) in patients hospitalized with acute decompensated heart failure (ADHF) 
have led to heterogeneous study outcomes. This meta-analysis aimed to assess the impact of UF therapy in ADHF patients. 
We searched the medical literature to identify well-designed studies comparing UF with the usual diuretic therapy in this 
setting. Systematic evaluation of 8 randomized controlled trials enrolling 801 participants showed greater fluid removal 
(difference in means 1372.5 mL, 95% CI 849.6 to 1895.4 mL; p < 0.001), weight loss (difference in means 1.592 kg, 95% 
CI 1.039 to 2.144 kg; p < 0.001) and lower incidences of worsening heart failure (OR 0.63, 95% CI 0.43 to 0.94, p = 0.022) 
and rehospitalization for heart failure (OR 0.54, 95% CI 0.36 to 0.82, p = 0.003) without a difference in renal impairment 
(OR 1.386, 95% CI 0.870 to 2.209; p = 0.169) or all-cause mortality (OR 1.13, 95% CI 0.75 to 1.71, p = 0.546). UF increases 
fluid removal and weight loss and reduces rehospitalization and the risk of worsening heart failure in congestive patients, 
suggesting ultrafiltration as a safe and effective treatment option for volume-overloaded heart failure patients.
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Abbreviations
UF  Ultrafiltration
ADHF  Acute decompensated heart failure
UC  Usual care
RCT  Randomized controlled trial
OR  Odds ratio
CI  Confidence interval
DM  Diabetes mellitus
ACE  Angiotensin-converting enzyme
ARB  Angiotensin II receptor blocker
NYHA  New York Heart Association
HF  Heart failure
Introduction
Heart failure (HF) is a clinical syndrome characterized by a 
group of symptoms (e.g., dyspnea, fatigue, and ankle swell-
ing) and signs (e.g., pulmonary crackles and peripheral 
edema) [1]. Acute decompensation is a common complica-
tion in patients with chronic HF.
Ultrafiltration (UF) is an upcoming treatment alterna-
tive for patients hospitalized for acute decompensated heart 
failure (ADHF). Fluid overload remains the main cause of 
heart failure hospitalization and is driven by sodium and 
water retention.[2] Thus, decongestion is one of the primary 
targets of therapy.
Mostly, decongestion has been accomplished through diu-
retic treatment. While 88% of affected patients are treated 
with diuretics, many show suboptimal responses, and hos-
pital readmission rates remain high (25% within 30 days) 
[3, 4]. Concerns related to the safety and efficacy of diuretic 
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treatment have also been raised. Furthermore, randomized 
controlled trials (RCTs) investigating the effects of diuret-
ics on mortality and morbidity are lacking.[1] Chronic and 
combined use of diuretics might lead to adverse effects such 
as diuretic resistance, electrolyte imbalances, and deteriorat-
ing renal function.[5] Such concerns have led to a growing 
interest in the development of novel therapeutic approaches 
for decongestion.
Ultrafiltration, a type of renal replacement therapy, is 
an invasive procedure that creates a transmembrane pres-
sure gradient driving plasma fluid across a semipermeable 
membrane. This technique can be used as an alternative to 
diuretic treatment for the removal of excess fluid in volume-
overloaded HF patients. Through technical improvements, 
UF devices have decreased in size, and their handling was 
simplified, which may contribute to the more extensive use 
of this therapeutic procedure in the future. Current guide-
lines promote the limited use of UF as a second-line treat-
ment option for patients failing to respond to diuretic therapy 
or for those developing diuretic resistance [1, 6].
However, the results of Costanzo et al. convincingly pro-
posed the use of UF as an initial treatment over diuretics 
in ADHF patients with volume overload [7, 8]. Costanzo 
et al. reported greater weight loss and fluid removal in the 
group treated with UF compared to the group treated with 
diuretics, as well as a 53% decreased risk of rehospitaliza-
tion after 6 months.
A number of small RCTs have investigated the influence 
of UF treatment compared to usual care therapy so far, but 
the results remain heterogeneous [9–11].
We performed this meta-analysis to investigate the possi-
ble advantages of UF compared to diuretic treatment regard-
ing fluid removal, weight loss, rehospitalization for HF, and 
all-cause mortality. Furthermore, incidences of adverse 




This meta-analysis is reported based on the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) Statement [12].
Search strategy
We searched MEDLINE (via PubMed), Embase, and the 
Cochrane Central Register of Controlled Trials (CENTRAL) 
to identify RCTs that compared ultrafiltration to “usual care” 
(diuretic therapy) in patients with ADHF. The date of the 
search was January 20, 2018, and the search was performed 
using the search terms “acute heart failure,” “ultrafiltration,” 
“diuretic agent” (for Embase and CENTRAL), or “diuret-
ics” (for MEDLINE) and filtered for randomized controlled 
human trials published in English.
Study selection
The initial screening of the articles was based on reading 
the titles and abstracts of the studies retrieved by our search 
strategy to determine suitability. After removing duplicates, 
a second evaluation was performed, which included reading 
the full-text articles. The references of the identified articles 
were manually searched for further relevant publications. 
The selection process was performed by two independent 
reviewers, and any disagreements were resolved through dis-
cussion. The process of inclusion and exclusion throughout 
the different phases is visually displayed using the PRISMA 
2009 Flow Diagram [12].
We applied the following eligibility criteria:
RCTs involving adults diagnosed with ADHF who pre-
sented signs and symptoms of congestion in which UF 
intervention was compared with usual care treatment using 
diuretic agents. For inclusion, studies needed to report one or 
more of the following study outcomes: fluid removal, weight 
loss, all-cause mortality, heart failure-related rehospitaliza-
tion, or adverse events, such as worsening heart failure or 
renal impairment (the latter was defined as an increase in 
serum creatinine level, a decrease in glomerular filtration 
rate, renal failure, or the need for dialysis).
We excluded those studies in which data seemed to be 
partly or completely evaluated in another selected study 
as well. Retrospective studies or studies without a control 
group were not included in our analysis.
Assessment of the risk of bias in included studies
The Cochrane Risk of Bias Tool for quality assessment 
of RCTs was used. We evaluated information concerning 
sequence generation, allocation concealment, blinding, 
outcome reporting, patient withdrawal, and other possible 
sources of bias.[13].
Data extraction
The extracted data included first author, year of publica-
tion, country of the study, patient inclusion and exclusion 
criteria, patient characteristics (number of patients, age, 
sex, medication, and comorbidities including hypertension 
and diabetes mellitus), details of the intervention (type of 
UF device, UF rate, and duration of UF session), details 
of the control-group protocol (type, dosage and administra-
tion route of diuretics), quality indicators (randomization, 
blinding, patient withdrawals/dropouts, and completion 
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of follow-up), and study outcomes such as fluid removal, 
weight loss, number of adverse events, all-cause mortality, 
rehospitalization for heart failure with time of measure-
ments, and follow-up duration.
Measures of treatment effect
The following primary outcomes were defined in our analy-
sis: (i) amount of fluid removal in milliliters, (ii) number of 
patients rehospitalized for HF during the follow-up, and (iii) 
incidences of adverse events such as worsening HF and renal 
impairment (defined as an increase in serum creatinine level, 
a decrease in glomerular filtration rate, renal failure or the 
need for dialysis). Secondary outcomes included (i) weight 
loss measured in kilograms and (ii) all-cause mortality dur-
ing follow-up.
Statistical analysis
Comprehensive Meta-Analysis (Version 3) statistical software 
(Biostat, Inc., Engelwood, MJ, USA) was used for data analy-
ses. In the case of binary outcomes, we calculated the pooled 
odds ratio (OR) and 95% confidence interval (CI), and in the 
case of continuous variables, we calculated the difference 
in means and standard error (SE). A fixed-effects model by 
Mantel–Haenszel was used in all cases since all the included 
studies were RCTs.[14] We suggested a statistically significant 
effect if the CI did not include 1 and the p value was less than 
0.05. Heterogeneity was tested using Cochran’s Q and the I2 
statistics.[13, 15] The Q homogeneity test statistic exceeds 
the upper-tail critical value of the chi-square on k–1 degrees 
of freedom. A p value of less than 0.1 was considered sug-
gestive of significant heterogeneity. The I2 statistic represents 
the percentage of the total variability across studies. Data are 
presented for visual comparisons using forest plots. Publica-
tion bias was examined by visual inspection of funnel plots, in 
which the SE was plotted against the net change for each study.
Results
Results of the search and description of studies
We initially identified 34 potentially relevant articles from 
the three different databases. After removing 12 duplicates, 
8 articles were excluded by the titles. Eighteen articles were 
included in the full-text review. After reading the abstracts 
and the full texts, 10 studies were excluded: 2 studies did 
not provide any data on the investigated outcomes, 6 articles 
were reviews, one study failed to provide a control group, 
and one study was excluded because it was a retrospective 
analysis. Additionally, we searched the references manually 
for relevant articles at this stage of our search. We identified 
4 further RCTs that were suitable for our analysis. Ulti-
mately, 8 RCTs were included in our meta-analysis (Fig. 1).
[7, 9–11, 16–19].
Table 1 shows the characteristics of the studies that were 
included in this meta-analysis, while the outcomes of the 
included studies are shown in Table 2. The 8 trials enrolled 
801 participants. The sample sizes of the included studies 
varied, ranging from 30 to 221. The UF rate ranged from 100 
to 500 mL/h, while different types of UF devices were used 
(Aquadex System 100, NxStage System One and PRISMA 
System). Loop diuretics (furosemide) were used in all trials, 
with a maximum dosage of up to 1446 mg/day.
Follow-up duration varied among studies and among 
evaluated parameters, ranging from 30 days to 12 months.
Quality assessment
The evaluation of possible bias within the studies 
revealed intermediate quality. Figure 2 shows a summary 
of our results [13]. Notably, blinding could scarcely be 
assessed in the studies because of the noticeable nature 
of the analyzed intervention (i.e., UF). The funding of 




Four studies provided data about patients suffering from 
worsening heart failure during follow-up [7, 11, 17, 18]. 
The incidence of worsening heart failure occurred in 76 
patients (34.2%) in the UF group and in 101 (45.7%) 
patients treated with diuretics. UF was associated 
with a significantly decreased risk of worsening heart 
failure (OR 0.632, 95% CI 0.426 to 0.936; p = 0.022, 
I2 = 67.4%).
Renal impairment
The incidence of renal impairment was reported in 5 studies, 
enrolling 675 patients in total [7, 9, 11, 17, 18]. A total of 331 
patients were randomized to the UF group, while 344 received 
usual care treatment. Renal impairment was observed in 50 
patients treated with UF and in 40 controls. We found a trend 
towards increased risk in usual care therapy, but this tendency 
failed to reach statistical significance (OR 1.386, 95% CI 0.870 
to 2.209; p = 0.169, I2 = 0%).




Seven studies enrolling 745 patients provided data on 
the extent of fluid removal [7, 9–11, 17, 18]. Treatment 
with ultrafiltration led to a significantly larger net vol-
ume of fluid removal compared to usual care (differ-
ence in means: 1372.5 mL, 95% CI 849.6 to 1895.4 mL; 
p < 0.001, I2 = 48.41%) (Fig. 3a). The time of measure-
ment for these outcomes ranged from 24 to 96 h, except 
for Marenzi, who measured fluid removal at hospital 
discharge, and Hanna, who measured the removal upon 
completion of the intervention.
Rehospitalization for heart failure
Heart failure-related rehospitalization was reported in 4 stud-
ies [7, 17–19]. Rehospitalization was reported for 50 out of 
316 patients in the UF group and for 88 out of 320 patients 
randomized to the UC group. UF resulted in a significant 
reduction in rehospitalization (OR 0.543; 95% CI 0.362 to 
Fig. 1  Flowchart of trial selection. Study selection flowchart according to PRISMA-P [12]
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Table 1  Characteristics of randomized controlled trials
First author Bart Bart Hanna Giglioli Seker Costanzo Marenzi Costanzo
Year 2005 2012 2012 2011 2016 2007 2014 2015
Country USA USA USA Italy Turkey USA Italy USA
Trial RAPID-CHF CARRESS ULTRADISCO UNLOAD CUORE AVOID-HF
Study design RCT RCT RCT RCT RCT RCT RCT RCT 
Reference 16 17 11 10 9 7 19 18
Sample size 40 188 36 30 30 200 56 221
Intervention group size 20 94 17 15 10 100 27 110
Control group size 20 94 19 15 20 100 29 111
Age (years) in UF group 67.5 66 60 72.4 66.5 62 75 67
Age (years) in UC group 69.5 69 59 65.8 66.8 63 73 67
Male (%) in UF group 70 72 84.2 87 60 70 81 69.1
Male (%) in UC group 70 78 76 87 65 68 83 73
Comorbidities
  Hypertension (%) in UF group 60 42.1 20 100 74 48 88.2
  Hypertension (%) in UC group 65 52.9 60 85 74 66 83
  DM (%) in UF group 35 67 36.8 40 60 50 59 61.8
  DM (%) in UC group 53 65 29.4 60 50 50 45 64
Medication
  ACE/ARB (%) in UF group 70 52 86.7 63 74 38.2
  ACE/ARB (%) in UC group 70 55 80 68 66 43.2
  Beta blocker (%) in UF group 75 78 66.7 65 74 52.7
  Beta blocker (%) in UC group 65 79 73.3 66 76 57.7
  Furosemide or equivalents (%) in UF 
group
65 96 100 72 100
  Furosemide or equivalents (%) in UC 
group
95 91 100 77 97
UF – ultrafiltration, UC – usual care, DM – diabetes mellitus, ACE – angiotensin-converting enzyme inhibitor, ARB – angiotensin II receptor 
blocker, HF – heart failure
Table 2  Outcomes of the included studies
First author Bart Bart Hanna Giglioli Seker Costanzo Marenzi Costanzo
Year 2005 2012 2012 2011 2016 2007 2014 2015
Intervention group size 20 94 17 15 10 100 27 110
Control group size 20 94 19 15 20 100 29 111
Worsening HF in UF group 31 2 39 4
Worsening HF in UC group 28 7 63 3
Renal impairment in UF group 17 8 2 21 2
Renal impairment in UC group 14 6 1 17 2
Rehospitalization for HF in UF group 23 16 1 10
Rehospitalization for HF in UC group 24 28 14 22
Deaths in UF group 1 16 4 4 9 7 17
Deaths in UC group 0 13 4 2 11 11 14
Weight loss in UF group (kg) 2.5 5.7 ± 3.9 4.7 ± 3.5 5.0 ± 3.1 7.5 ± 5.5 10.7 ± 7.2
Weight loss in UC group (kg) 1.86 5.5 ± 5.1 1.0 ± 2.5 3.1 ± 0.75 7.9 ± 9.0 10.3 ± 9.2
Fluid removal in UF group (mL) 8415 7443 ± 4329 5215 ± 3406 11086 ± 1786 7872 ± 1829 4600 ± 2600 12900
Fluid removal in UC group (mL) 5375 7082 ± 4183 2167 ± 2380 10425 ± 3002 6882 ± 4221 3300 ± 2600 8900
UF – ultrafiltration, UC – usual care, AE – adverse events, RCT – randomized controlled trial, DM – diabetes mellitus, ACE – angiotensin-
converting enzyme inhibitor, ARB – angiotensin II receptor blocker
581 Heart Failure Reviews (2021) 26:577–585
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0.815; p = 0.003, I2 = 68.4%) (Fig. 3b). The follow-up dura-
tion for evaluation of rehospitalization ranged from 30 days 
[7], 60 days [16], and 90 days [18] to 1 year [19].
Weight loss
Data on weight loss were reported in 5 studies [7, 11, 17–19] 
and included 741 patients in total. Weight loss in the UF group 
was significantly greater than weight loss in patients treated 
with usual care (difference in means 1.592 kg, 95% CI 1.039 to 
2.144 kg; p < 0.001, I2 = 65.88%). Weight loss was evaluated 
at 24 to 96 h, except for Marenzi et al., who measured weight 
loss at hospital discharge, and Hanna et al., who measured 
weight loss at the end of the intervention period.
All‑cause mortality
All-cause mortality was reported in 7 studies and occurred 
in 58 out of 378 patients in the UF group and in 57 out of 
393 patients in the UC group [7, 9–11, 17–19]. Our analysis 
showed no difference in mortality between the two groups 
(OR 1.134; 95% CI 0.754 to 1.706; p = 0.546, I2 = 0%). The 
follow-up duration ranged from 30 days to 1 year.
Risk of bias within studies
The results of the Cochrane Risk of Bias Tool for quality 
assessment of RCTs are displayed in Fig. 2. The industry 
funding of two included studies represents a possible special 
source of bias [7, 16].
The testing of heterogeneity across studies using Cochran’s 
Q and the I2 statistics reveals varying results for the investi-
gated parameters. While our analysis found no evidence of 
heterogeneity for renal impairment (Q test p = 0.858; I2 = 0%), 
fluid removal (Q test p = 0.071; I2 = 48.4%), or all-cause 
mortality (Q test p = 0.504; I2 = 0%), there was evidence of 
Fig. 2  Assessment of risk of bias of included studies. Risk of bias 
summary according to the Cochrane Risk of Bias Tool for quality 
assessment  of randomized controlled trials. Low risk of bias (plus-
sign), unclear risk of bias (question mark) and high risk  of bias 
(minus-sign). Short-term outcomes: fluid removal and weight loss. 
Long-term outcomes: adverse events, rehospitalization for heart fail-
ure (HF) and all-cause mortality
Fig. 3  Forest plot of a fluid removal and b worsening heart fail-
ure  a: Forest plot comparing the mean difference in fluid removal 
between the control and intervention groups. b: Forest plot compar-
ing odds ratios of rehospitalization for heart failure. Squares represent 
odds  ratios of rehospitalization for heart failure. Squares represent 
oddsratios of HF-related  rehospitalization in the UF versus control 
group. The size of the square is proportional to the study weight. 
Error bars represent the 95% confidence interval. Diamonds represent 
pooled estimates for odds ratios with 95% CIs
582 Heart Failure Reviews (2021) 26:577–585
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heterogeneity for worsening HF (Q test p = 0.027; I2 = 67.4%), 
rehospitalization for HF (Q test p = 0.023; I2 = 68.4%), and 
weight loss (Q test p = 0.0195; I2 = 65.9%).
Assessment of publication bias
Visual inspection of the funnel plots showed no evidence 
of publication bias for fluid removal (Fig. 4a), but visual 
evidence of publication bias was observed in the funnel plot 
for all-cause mortality (Fig. 4b).
Discussion
In this meta-analysis of 8 studies involving 801 patients, we 
demonstrated the potential of UF to remove an increased vol-
ume of fluid compared with diuretic treatment, while showing 
no increased risk of deterioration in renal function in volume-
overloaded HF patients. Moreover, UF reduces the risks of 
worsening HF and rehospitalization for HF.
Our findings implicate UF as a valid treatment alternative 
to diuretics in this patient population. The present evaluation 
is congruent with a previous review, which showed that UF 
treatment effectively removed larger volumes of fluid without 
significant changes in serum creatinine levels [20].
In these high-risk populations, with a considerable preva-
lence of cardiorenal syndrome, preservation of kidney func-
tion is an important task [21]. Patients developing renal failure 
and requiring dialysis exhibit a 2.7-fold increase in mortality 
within 12 months compared with those who do not show renal 
insufficiency (95% vs. 35%).[22]
Importantly, UF improves quality of life to a similar extent 
as diuretic treatment [18]. Bart et al. found improved results for 
dyspnea scores and congestive HF symptoms after UF therapy 
[16]. In a meta-analysis by Kabach et al., UF was associated 
with a reduced risk of clinical worsening and an increased 
likelihood for clinical decongestion; however, UF was found to 
have no effect on rates of rehospitalization and mortality [23]. 
While the meta-analysis by Kabach et al. was able to prove the 
advantages of UF in terms of decongestion, we were able to 
not only reproduce some of their findings but also emphasize 
the advantages of UF in preserving renal function and lower-
ing rates of rehospitalization with the addition of two more 
recent RCTs.
In our present study, we showed a sustained advantage of 
UF treatment over usual care regarding the number of HF-
related rehospitalizations between 30 days and 12 months 
after therapy. Long-lasting benefits of UF therapy were also 
described by Agostoni et al., who reported increased exercise 
performance that persisted for 3 months, as well as improved 
pulmonary function and lowered norepinephrine levels at 
rest that lasted up to 6 months after UF therapy in congestive 
HF patients.[24] While chronic diuretic treatment appears to 
have negative effects on neurohormonal activation, UF may 
contribute to the sustained benefit regarding rehospitaliza-
tion by decreasing the activation of the neurohormonal axis, 
although the available data remain contradictory. Agostoni 
et al. reported a significant decrease in plasma renin activ-
ity and serum levels of norepinephrine and aldosterone after 
UF therapy [24]. While Giglioli et al. were able to reproduce 
these findings for aldosterone, Seker et al. found no differ-
ence between the groups for renin and aldosterone levels [9]. 
Moreover, an analysis of the CARRESS trial found higher 
plasma renin activity among patients treated with UF than 
among those in the diuretic therapy group [25].
UF might reduce the diuretic dose needed to preserve 
the patient’s euvolemia. Costanzo et al. described sig-
nificantly lower doses needed in the UF group at 10 days 
after discharge than in the diuretic group.[7] Similarly, 
Marenzi et al. reported that the UF group needed signifi-
cantly lower doses of diuretics at the 12-month follow-up 
[19]. The ESCAPE trial revealed a strong correlation 
between the in-hospital loop diuretic dose and 6-month 
mortality. Notably, the dose remained a significant pre-
dictor of mortality.[26] Our analysis found no influence 
on all-cause mortality.
Fig. 4  Funnel plot for visualization of publication bias across studies for fluid removal a and all-cause mortality b 
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It should also be mentioned that our analysis has some 
limitations. First, we detected considerable differences 
in the intervention protocols (UF rate, diuretic dosage, 
etc.) and time of measurement across the included stud-
ies. Thus, clinical diversity might have influenced the 
outcome of this analysis. Second, we found possible risks 
of bias within the studies. In particular, funding might 
have influenced the results [7, 16]. Third, our analysis 
found evidence of heterogeneity for certain outcomes, 
which might be explained by the small number of studies. 
Fourth, different search terms were used to identify suit-
able studies during the selection process. Search terms 
were individually adapted to the databases to obtain a 
high number of results.
This analysis supports the efficacy and safety of UF 
therapy. UF has the potential to remove a larger net 
volume of fluid without increasing the risk of adverse 
events. However, the lack of physician experience with 
extracorporeal therapies, the need for veno-venous access 
and the associated costs for the device and related dispos-
able items are obvious disadvantages and obstacles to 
the widespread use of this technique. Further studies are 
necessary to investigate the adverse events related to UF 
treatment, specifically identify its potential advantages 
and clearly define patient populations that may benefit 
most from primary or early UF treatment.
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